Gujarat Themis Biosyn Limited

158 Million

+ Dossiers + Inventory); No transfer of manufacturing facilities or employees Deal worth ~ EURO 158 Million – funded by optimal mix of debt and equity Acquisition subject to obtaining antitrust and foreign

70%

FOLIO METRICS PRODUCTS IN PORTFOLIO GLOBAL REACH (COUNTRIES) 13 55+ RETAIL CHANNEL CONTRIBUTION ~70% ~62M FY25 REVENUE (EURO) Driving Global Scale and Value Chain Integration after closing Global E

rs,

DYNAMICS Global TB Burden Tuberculosis remains one of the world's leading infectious disease killers, driving sustained demand for anti-TB therapies. Antimicrobial Resistance Focus Increasing global f

Sub

1

Investor Relations Advisors

1

Sub

Investor Presentation In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), we submit herewith the Investors’ Presentation of the Gujarat Themis Biosyn Limited (‘the Company’) with respect to asset purchase of Sanofi’s Global Anti-TB and Anti-Infective Portfolio. Further, a copy of the same is also available on the website of the Company, viz., www.gtbl.in Kindly take the same on record and acknowledge receipt of the same. Thanking you, Yours faithfully, For Gujarat Themis Biosyn Limited Vineet Gawankar Company Secretary and Compliance Officer MUMBAI OFFICE: Themis House, 11/12 Udyog Nagar, S.V Road, Goregaon (West), Mumbai – 400 104 Tel: 91-22-67607080 / 28757836 Fax: 28746621 / 67607019; E-mail: gtblmumbai@gtbl.in Website Address: www.gtbl.in Gujarat Themis Biosyn Limited Portfolio Acquisition Agreement with Sanofi (the French-holding company of the Sanofi group) to Acquire Select Product Portfolio Asset acquisition st

Investor Relations Advisors

Gujarat Themis Biosyn Limited Adfactors PR Pvt. Ltd. Mr. Krupesh Patel Chief Financial Officer krupesh.patel@themismedicare.com www.gtbl.in Mr. Rahul Trivedi Ms. Saloni Nagvekar rahul.trivedi@adfactorspr.com saloni.nagvekar@adfactorspr.com www.adfactorspr.com